Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity
Authors
Keywords
-
Journal
BIOMATERIALS
Volume 296, Issue -, Pages 122062
Publisher
Elsevier BV
Online
2023-02-22
DOI
10.1016/j.biomaterials.2023.122062
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines
- (2022) Siri Tahtinen et al. NATURE IMMUNOLOGY
- Immunostimulatory Polymers as Adjuvants, Immunotherapies, and Delivery Systems
- (2022) Adam M. Weiss et al. MACROMOLECULES
- Inflammasomes and adaptive immune responses
- (2021) Katherine A. Deets et al. NATURE IMMUNOLOGY
- Select hyperactivating NLRP3 ligands enhance the TH1- and TH17-inducing potential of human type 2 conventional dendritic cells
- (2021) Lukas Hatscher et al. Science Signaling
- Cancer Vaccines, Adjuvants, and Delivery Systems
- (2021) Samantha J. Paston et al. Frontiers in Immunology
- The AIM2 and NLRP3 inflammasomes trigger IL-1–mediated antitumor effects during radiation
- (2021) Chuanhui Han et al. Science Immunology
- NLRP3 Inflammasome: A Promising Therapeutic Target for Drug-Induced Toxicity
- (2021) Shanshan Wei et al. Frontiers in Cell and Developmental Biology
- Biodistribution of extracellular vesicles following administration into animals: A systematic review
- (2021) Matthew Kang et al. Journal of Extracellular Vesicles
- Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens
- (2020) Geoffrey M. Lynn et al. NATURE BIOTECHNOLOGY
- Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics
- (2020) Simon Van Herck et al. ACTA PHARMACOLOGICA SINICA
- A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer
- (2020) Qianqian Ni et al. Science Advances
- IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy
- (2020) Ting Zhou et al. NATURE
- Proton-driven transformable nanovaccine for cancer immunotherapy
- (2020) Ningqiang Gong et al. Nature Nanotechnology
- Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients
- (2020) Emilio Francesco Giunta et al. Scientific Reports
- Increased vaccine tolerability and protection via NF-κB modulation
- (2020) B. A. Moser et al. Science Advances
- Mitigation of Hydrophobicity-Induced Immunotoxicity by Sugar Poly(orthoesters)
- (2019) Sampa Maiti et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Targeted antibody and cytokine cancer immunotherapies through collagen affinity
- (2019) Jun Ishihara et al. Science Translational Medicine
- At the bench: Engineering the next generation of cancer vaccines
- (2019) Daniel Shae et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Current challenges for cancer vaccine adjuvant development
- (2018) William S. Bowen et al. Expert Review of Vaccines
- Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses
- (2018) Emilie Seydoux et al. JOURNAL OF IMMUNOLOGY
- A facile approach to enhance antigen response for personalized cancer vaccination
- (2018) Aileen Weiwei Li et al. NATURE MATERIALS
- Immunomodulation of the NLRP3 Inflammasome through Structure-Based Activator Design and Functional Regulation via Lysosomal Rupture
- (2018) Saikat Manna et al. ACS Central Science
- Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses
- (2018) Lutz Nuhn et al. ADVANCED MATERIALS
- Physical activation of innate immunity by spiky particles
- (2018) Ji Wang et al. Nature Nanotechnology
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- P2X7 receptor and NLRP3 inflammasome activation in head and neck cancer
- (2017) Ju Young Bae et al. Oncotarget
- Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18
- (2016) Z. Ma et al. CLINICAL CANCER RESEARCH
- Designer vaccine nanodiscs for personalized cancer immunotherapy
- (2016) Rui Kuai et al. NATURE MATERIALS
- Enhancing Endosomal Escape for Intracellular Delivery of Macromolecular Biologic Therapeutics
- (2016) Peter Lönn et al. Scientific Reports
- The Nlrp3 Inflammasome Suppresses Colorectal Cancer Metastatic Growth in the Liver by Promoting Natural Killer Cell Tumoricidal Activity
- (2015) Jeremy Dupaul-Chicoine et al. IMMUNITY
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors
- (2014) By Zhao et al. Journal for ImmunoTherapy of Cancer
- Self-Assembled Peptide Amphiphile Micelles Containing a Cytotoxic T-Cell Epitope Promote a Protective Immune Response In Vivo
- (2012) Matthew Black et al. ADVANCED MATERIALS
- The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system
- (2011) Abbi L Engel et al. Expert Review of Clinical Pharmacology
- Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome
- (2009) Fiona A. Sharp et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now